Author: Corbett, Kizzmekia S.; Edwards, Darin K.; Leist, Sarah R.; Abiona, Olubukola M.; Boyoglu-Barnum, Seyhan; Gillespie, Rebecca A.; Himansu, Sunny; Schäfer, Alexandra; Ziwawo, Cynthia T.; DiPiazza, Anthony T.; Dinnon, Kenneth H.; Elbashir, Sayda M.; Shaw, Christine A.; Woods, Angela; Fritch, Ethan J.; Martinez, David R.; Bock, Kevin W.; Minai, Mahnaz; Nagata, Bianca M.; Hutchinson, Geoffrey B.; Wu, Kai; Henry, Carole; Bahi, Kapil; Garcia-Dominguez, Dario; Ma, LingZhi; Renzi, Isabella; Kong, Wing-Pui; Schmidt, Stephen D.; Wang, Lingshu; Zhang, Yi; Phung, Emily; Chang, Lauren A.; Loomis, Rebecca J.; Altaras, Nedim Emil; Narayanan, Elisabeth; Metkar, Mihir; Presnyak, Vlad; Liu, Cuiping; Louder, Mark K.; Shi, Wei; Leung, Kwanyee; Yang, Eun Sung; West, Ande; Gully, Kendra L.; Stevens, Laura J.; Wang, Nianshuang; Wrapp, Daniel; Doria-Rose, Nicole A.; Stewart-Jones, Guillaume; Bennett, Hamilton; Alvarado, Gabriela S.; Nason, Martha C.; Ruckwardt, Tracy J.; McLellan, Jason S.; Denison, Mark R.; Chappell, James D.; Moore, Ian N.; Morabito, Kaitlyn M.; Mascola, John R.; Baric, Ralph S.; Carfi, Andrea; Graham, Barney S.
Title: SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness Cord-id: 1tmqe3xf Document date: 2020_8_5
ID: 1tmqe3xf
Snippet: A severe acute respiratory syndrome coronavirus (SARS-CoV-2) vaccine is needed to control the global coronavirus infectious disease (COVID-19) public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins(1). Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabiliz
Document: A severe acute respiratory syndrome coronavirus (SARS-CoV-2) vaccine is needed to control the global coronavirus infectious disease (COVID-19) public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins(1). Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody responses to wild-type (D614) and D614G mutant(2) SARS-CoV-2 and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in Phase 3 efficacy evaluation.
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date